CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Benlysta (belimumab) coverage for SLE and Lupus Nephritis

Medical and pharmacy coverage criteria for Benlysta (belimumab) for treatment of systemic lupus erythematosus (SLE) and lupus nephritis, governing Medicaid, Commercial, and Medicare-Medicaid Plan (MMP) members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyBenlysta (belimumab) coverage for SLE and Lupus Nephritis

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateSep 1, 2017

Next Review DateN/A

Key ActionSubmit prior authorization demonstrating age eligibility, documented active disease with required activity scores, prior therapy failures, and baseline labs for lupus nephritis.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 yearsminimum age for SLE treatment

6 monthsinitial coverage duration

J0490HCPCS code

4/28dSQ quantity limit

10 mg/kgIV dosing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Benlysta (belimumab)

Initial Therapy - SLE

Covered when ALL of the following are met

SLE Initial Criteria: Patient is 5 years of age or older; documented diagnosis of active SLE; AND meets one of the disease activity measures: SELENA-SLEDAI score 6-12 OR BILAG B organ domain score >=2; AND failed to respond adequately to at least two (2) standard therapies such as antimalarials, corticosteroids, NSAIDs, or immunosuppressives (excluding intravenous cyclophosphamide); AND used in combination with standard therapy (e.g., antimalarials, corticosteroids, NSAIDs, immunosuppressives); AND no active infection; AND has not received a live vaccine within 30 days before starting or concurrently with Benlysta; AND will not be used in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab); AND does not have severe active central nervous system lupus or be receiving other biologic therapy.

Includes pediatric age allowance per product labeling (see subcutaneous formulation age/weight notes).

Initial Therapy - Lupus Nephritis

Covered when ALL of the following are met

Lupus Nephritis Initial Criteria: Patient is 5 years of age or older; active lupus nephritis Class III, IV, or V confirmed by renal biopsy; AND failed to respond adequately to standard therapies including corticosteroids and either cyclophosphamide or mycophenolate mofetil; AND provided baseline measurement of one or more: urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein; AND used in combination with standard therapy (e.g., antimalarials, corticosteroids, NSAIDs, immunosuppressives); AND no active infection; AND has not received a live vaccine within 30 days before starting or concurrently with Benlysta; AND will not be used in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab); AND does not have severe active central nervous system lupus or be receiving other biologic therapy.

Product labeling notes age distinctions for subcutaneous formulations (see labeling footnotes).

Continuation of Therapy

Continued coverage when ALL of the following are met

General continuation: Patient continues to meet all applicable initial therapy criteria and is tolerating treatment without unacceptable toxicity (examples: depression, suicidal thoughts, serious infections, signs/symptoms of PML, malignancy, severe hypersensitivity/anaphylaxis, serious infusion reactions).

SLE response measures: Documentation of disease stability or improvement versus pre-treatment baseline by one or more of: improvement in SELENA-SLEDAI score >=4; OR no new BILAG-A organ domain score or 2 new BILAG-B organ domain scores; OR no worsening (<30 point increase) in Physician's Global Assessment (PGA); OR seroconversion (negative) or >=20% reduction in autoantibody level.SELENA-SLEDAI >=4 improvement; PGA <30 point increase; autoantibody reduction >=20%

Lupus nephritis response measures: Documentation of disease stability or improvement compared to baseline by one or more of: urine protein:creatinine ratio (uPCR), estimated GFR (eGFR), or urine protein.

Coverage of belimumab (Benlysta) excludes its use in combination with certain other targeted therapies and concurrent biologic agents. Specifically, Benlysta will not be used in combination with Lupkynis (voclosporin) or Saphnelo (anifrolumab). Requests for treatment will also be excluded for individuals who are receiving other biologic therapies concurrently or who have severe active central nervous system lupus, per the policy exclusions.

Benlysta is considered not medically necessary when the patient does not meet the policy’s disease activity or prior-therapy requirements, or when safety conditions are present. Examples include patients who fail to meet specified activity thresholds (e.g., SELENA‑SLEDAI 6–12 or BILAG B organ domain ≥2 for SLE), patients who have not failed at least two standard therapies (for SLE) or who have not failed corticosteroids plus either cyclophosphamide or mycophenolate (for lupus nephritis), patients with an active infection, or patients who received a live vaccine within 30 days before or concurrently with therapy. Use is also not medically necessary for patients on excluded concomitant biologics or with severe active CNS lupus.

Coding and Dosing Information

Covered HCPCS/CPT CodesHCPCSCovered

J0490

Injection, belimumab, 10mg

SELENA-SLEDAI improvement

Required SELENA-SLEDAI improvement>= 4-point improvement from pre-treatment baseline

PurposeDocumentation of disease stability or improvement for continuation of therapy

Comparison timepointCompared to pre-treatment baseline SELENA-SLEDAI score

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Benlysta. Requests must include required clinical documentation and will be reviewed against the coverage criteria. Failure to provide complete documentation or meet clinical thresholds may result in denial.

Prior authorization is required for Benlysta (belimumab).
Initial coverage period: 6 months; continuation: 6 months.

Documentation Required

Provider Documentation Required

Provide complete, specific clinical documentation with the prior authorization request. Include the documented diagnosis and objective disease activity measures. Missing or insufficient documentation is a common reason for denial.

Documented diagnosis of active Systemic Lupus Erythematosus (SLE) or active lupus nephritis (Class III, IV, or V) as applicable.
Disease activity measures such as SELENA-SLEDAI score (e.g., 6–12) or BILAG organ domain scores (B score ≥2) for SLE.

Clinical Definitions and Scoring

SELENA-SLEDAI score

SELENA-SLEDAI score used for eligibilityScore of 6-12 is referenced as an initial eligibility threshold

Role in coverageOne of the disease activity measures required for initial SLE coverage

Use in continuationChange of >=4-point improvement is used to document response for continuation

BILAG scoring

BILAG organ domain criterionBILAG B organ domain score >=2 is accepted as alternate initial eligibility

Continuation metricNo new BILAG-A organ domain score or 2 new BILAG-B scores is an accepted continuation measure

Context of use

Background and Therapeutic Context

Belimumab (Benlysta) is an adjunctive biologic therapy indicated for the treatment of active systemic lupus erythematosus (SLE) and for lupus nephritis in specified populations. The policy references pivotal trial evidence supporting clinical benefit when belimumab is added to standard therapy (improvements in disease activity and reduced flares in SLE). Product-specific pediatric notes and formulation distinctions are reflected in the age and weight eligibility criteria for subcutaneous preparations.

Revision History

2017-09-01policy_effective

Policy effective date established for BENLYSTA (belimumab).

2017-09-01policy_review

Initial review recorded and subsequent periodic reviews began (listed reviews include 9/2017).

2018-12-01policy_review

Policy reviewed (December 2018).

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyBenlysta (belimumab) coverage for SLE and Lupus Nephritis

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateSep 1, 2017

Next Review DateN/A

Key ActionSubmit prior authorization demonstrating age eligibility, documented active disease with required activity scores, prior therapy failures, and baseline labs for lupus nephritis.

SourceLink

On This Page

Baseline and follow-up measurements for lupus nephritis such as urine protein:creatinine ratio (uPCR), estimated glomerular filtration rate (eGFR), or urine protein.

History of prior therapies and failures to at least two standard therapies for SLE (antimalarials, corticosteroids, NSAIDs, immunosuppressives — excluding IV cyclophosphamide) or failure to corticosteroids plus either cyclophosphamide or mycophenolate mofetil for lupus nephritis.

Confirmation that patient is age-eligible (see clinical criteria) and that no live vaccine was given within 30 days before or concurrently with therapy.

Denial Risk

Step Therapy Exemption and Denial Risks

Step therapy exemptions and denial conditions: members who received Benlysta within the past 365 days are exempt from step therapy; however, requests may be denied for patients who do not meet age or disease activity criteria or when required prior therapy failures or documentation are not provided.

Members who have received Benlysta within the past 365 days are exempt from Step Therapy requirements.
Requests may be denied if the patient is younger than the policy age requirement (see clinical criteria) or if diagnosis of active disease is not documented.
Requests may be denied if disease activity thresholds are not met (e.g., missing SELENA‑SLEDAI or BILAG scores) or if objective measures for lupus nephritis (uPCR, eGFR, urine protein) are absent.
Requests may be denied if prior therapy history does not document failures to the required standard therapies.
Requests may be denied if the patient has an active infection, received a live vaccine within 30 days, or is receiving disallowed concomitant biologic therapies (e.g., voclosporin or anifrolumab).

BILAG may be used instead of SELENA-SLEDAI to demonstrate active disease or response

2019-11-01policy_review

Policy reviewed (November 2019).

2020-09-01policy_review

Policy reviewed (September 2020).

2021-01-01policy_review

Policy reviewed (January 2021).

2021-04-01policy_review

Policy reviewed (April 2021).

2022-01-01policy_review

Policy reviewed (January 2022).

2022-09-01policy_review

Policy reviewed (September 2022).

2023-01-01policy_review

Policy reviewed (January 2023).

2023-12-01policy_review

Policy reviewed (December 2023).

2024-01-01policy_review

Policy reviewed (January 2024).

2024-08-01policy_review

Policy reviewed (August 2024).

2025-03-01policy_reviewLatest

Most recent policy review (March 2025).